Fondation Brugmann

Projet mené par Jeroen de Filette : 'Immune checkpoint inhibitors are the current standard of care for many malignancies, due to its unique mechanism of releasing the brakes of the immune system. The flip side are immune-related adverse events, including skin, intestinal and endocrine toxicity, although any organ system can be affected. The purpose of the present study is to evaluate the association between the autoimmune endocrine disease-related antibodies, the development of the endocrine irAE and the tumor response'